Vaccine development as a means to control dengue virus pathogenesis: Do we know enough?

Annual Review of Virology

Volumn 1, Issue 1, 2014, Pages 375-398

  Pierson, Theodore C ^a   Diamond, Michael S ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Cellular immunity; Flavivirus; Humoral immunity; Neutralization; Pathogenesis

Indexed keywords

ANTIBODY; CHIMERIC YELLOW FEVER DENGUE TETRAVALENT DENGUE VACCINE; DENGUE VACCINE; DNA PLASMID VACCINE; DNA VACCINE; LIVE VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ALLERGY; ARTICLE; ASSAY; CLINICAL TRIAL (TOPIC); DENGUE; DENGUE VIRUS; DYNAMICS; FLAVIVIRUS; GENETIC VARIABILITY; HEALTH; HUMAN; INFECTION; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; SEROTYPE; T LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN;

DENGUE VIRUS; DENGUE VIRUS GROUP; FLAVIVIRUS; RNA VIRUSES;

EID: 85016959543     PISSN: 2327056X     EISSN: 23270578     Source Type: Journal    
DOI: 10.1146/annurev-virology-031413-085453     Document Type: Article

References (154)

1. Rush AB. 1789. An account of the bilious remitting fever, as it appeared in Philadelphia, in the summer and autumn of the year 1780. In Medical Inquiries and Observations, pp. 104-17. Philadelphia: Prichard & Hall
2. Kuno G. 2007. Research on dengue and dengue-like illness in East Asia and theWestern Pacific during the first half of the 20th century. Rev. Med. Virol. 17:327-41
3. Mackenzie JS, Gubler DJ, Petersen LR. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis,West Nile and dengue viruses. Nat. Med. 10:S98-109
4. Bhatt S,Gething PW, Brady OJ, Messina JP, Farlow AW, et al. 2013. The global distribution and burden of dengue. Nature 496:504-7
5. HammonWM, Rudnick A, Sather G, Rogers KD,Morse LJ. 1960. New hemorrhagic fevers of children in the Philippines and Thailand. Trans. Assoc. Am. Physicians 73:140-55
6. Kouri GP, Guzman MG, Bravo JR, Triana C. 1989. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull. World Health Organ. 67:375-80
7. Pierson TC, Kielian M. 2013. Flaviviruses: braking the entering. Curr. Opin. Virol. 3:3-12
8. Zaitseva E, Yang ST, Melikov K, Pourmal S, Chernomordik LV. 2010. Dengue virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathog. 6:e1001131
9. Lindenbach BD, Rice CM. 2003. Molecular biology of flaviviruses. Adv. Virus Res. 59:23-61
10. Elshuber S, Allison SL, Heinz FX,Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 84:183-91
11. Stadler K, Allison SL, Schalich J, Heinz FX. 1997. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 71:8475-81
12. Kaufmann B, Rossmann MG. 2011. Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect. 13:1-9
13. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, et al. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4:e1000060
14. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, et al. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830-34
15. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-25
16. Nybakken G, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis for neutralization of a therapeutic antibody against West Nile virus. Nature 437:764-69
17. Kaufmann B, Nybakken G, Chipman PR, Zhang W, Fremont DH, et al. 2006. West Nile virus in complex with a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. USA 103:12400-4
18. Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, et al. 2010. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. USA 107:18950-55
19. de Alwis R, Smith SA,Olivarez NP,Messer WB, Huynh JP, et al. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. USA 109:7439-44
20. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, et al. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4:139ra183
21. Balmaseda A, Hammond SN, Tellez Y, Imhoff L, Rodriguez Y, et al. 2006. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop. Med. Int. Health 11:935-42
22. BurkeDS, Nisalak A, Johnson DE, Scott RM. 1988. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38:172-80
23. Endy TP, Chunsuttiwat S,Nisalak A, LibratyDH, Green S, et al. 2002. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am. J. Epidemiol. 156:40-51
24. Sabin AB. 1952. Research on dengue duringWorld War II. Am. J. Trop. Med. Hyg. 1:30-50
25. Seet RC, Quek AM, Lim EC. 2007. Post-infectious fatigue syndrome in dengue infection. J. Clin. Virol. 38:1-6
26. Halstead SB. 2007. Dengue. Lancet 370:1644-52
27. World Health Organ. (WHO). 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva:WHO. 3rd ed.
28. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9
29. Murgue B, Roche C, Chungue E, Deparis X. 2000. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60:432-38
30. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, et al. 2002. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185:1213-21
31. Ngo NT, Cao XT, Kneen R, Wills B, Nguyen VM, et al. 2001. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin. Infect. Dis. 32:204-13
32. GuzmanMG,KouriG, Valdes L, Bravo J, Vazquez S,Halstead SB. 2002. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica 11:223-27
33. Halstead SB,Nimmannitya S, Cohen SN. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42:311-28
34. Graham RR, JuffrieM, Tan R, Hayes CG, Laksono I, et al. 1999. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia. I. Studies in 1995-1996. Am. J. Trop. Med. Hyg. 61:412-19
35. Jain A, ChaturvediUC. 2010. Dengue in infants: an overview. FEMS Immunol. Med. Microbiol. 59:119-30
36. Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, et al. 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196:416-24
37. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop.Med. Hyg. 38:411-19
38. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. 2009. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6:e1000171
39. Bharaj P, Chahar HS, Pandey A, Diddi K, Dar L, et al. 2008. Concurrent infections by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, India. Virol. J. 5:1
40. Wilder-Smith A, Gubler DJ. 2008. Geographic expansion of dengue: the impact of international travel. Med. Clin. N. Am. 92:1377-90
41. Kyle JL, Harris E. 2008. Global spread and persistence of dengue. Annu. Rev. Microbiol. 62:71-92
42. Sabin AB, Schlesinger RW. 1945. Production of immunity to dengue with virusmodified by propagation in mice. Science 101:640-42
43. Theiler M, Smith HH. 1937. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65:787-800
44. Yauch LE, Shresta S. 2014. Dengue virus vaccine development. Adv. Virus Res. 88:315-72
45. Barrett AD, Teuwen DE. 2009. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol. 21:308-13
46. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:7229-41
47. Monath TP. 2005. Yellow fever vaccine. Expert Rev. Vaccines 4:553-74
48. Beck A, Tesh RB, Wood TG, Widen SG, Ryman KD, Barrett AD. 2013. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J. Infect. Dis. 209:334-44
49. Whitehead SS, Hanley KA, Blaney JE Jr, Gilmore LE, Elkins WR, Murphy BR. 2003. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21:4307-16
50. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, et al. 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVaxTM-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccines 2:60-67
51. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201:370-77
52. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-67
53. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. 2011. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:7242-50
54. Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, et al. 2001. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am. J. Trop. Med. Hyg. 65:414-19
55. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, et al. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am. J. Trop. Med. Hyg. 65:405-13
56. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, et al. 2013. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J. Infect. Dis. 207:957-65
57. Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, et al. 1996. Testing of a dengue 2 liveattenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14:329-36
58. Butrapet S, HuangCY, Pierro DJ, Bhamarapravati N, Gubler DJ, KinneyRM.2000. Attenuationmarkers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J. Virol. 74:3011-19
59. Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, et al. 2013. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl. Trop. Dis. 7:e2243
60. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. 2011. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29:7267-75
61. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, et al. 2006. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24:1238-41
62. Clements DE,Coller BA, LiebermanMM,Ogata S,WangG, et al. 2010. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705-15
63. Danko JR, Beckett CG, Porter KR. 2011. Development of dengue DNA vaccines. Vaccine 29:7261-66
64. Kochel T, Wu SJ, Raviprakash K, Hobart P, Hoffman S, et al. 1997. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15:547-52
65. Porter KR,KochelTJ,WuSJ, Raviprakash K, Phillips I,Hayes CG. 1998. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch. Virol. 143:997-1003
66. Konishi E, Yamaoka M, Kurane I, Mason PW. 2000. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18:1133-39
67. Ferlenghi I, Clarke M, Ruttan T, Allison SL, Schalich J, et al. 2001. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol. Cell 7:593-602
68. Hughes HR, Crill WD, Chang GJ. 2012. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol. J. 9:115
69. Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, et al. 2011. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 29:960-68
70. PiersonTC, DiamondMS. 2013. Flaviviruses. In Fields Virology, ed.DMKnipe,PMHowley, pp. 747-94. Philadelphia: LippincottWilliams & Wilkins. 6th ed.
71. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229-38
72. Rico-Hesse R. 1990. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 174:479-93
73. Holmes EC, Twiddy SS. 2003. The origin, emergence and evolutionary genetics of dengue virus. Infect. Genet. Evol. 3:19-28
74. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, et al. 2010. Genotype specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84:10630-43
75. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. 2010. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 6:e1000821
76. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, et al. 2009. Structural basis for the preferential binding of immature flaviviruses by a fusion-loop specific antibody. EMBO J. 28:3269-76
77. Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, et al. 2010. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 84:8353-58
78. Pierson TC, DiamondMS. 2012. Degrees of maturity: the complex structure and biology of flaviviruses. Curr. Opin. Virol. 2:168-75
79. Mukherjee S, Lin TY, Dowd KA, Manhart CJ, Pierson TC. 2011. The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases. J. Virol. 85:12067-72
80. Boehr DD, Wright PE. 2008. How do proteins interact? Science 320:1429-30
81. Mateu MG. 2013. Assembly, stability and dynamics of virus capsids. Arch. Biochem. Biophys. 531:65-79
82. Lewis JK, Bothner B, Smith TJ, Siuzdak G. 1998. Antiviral agent blocks breathing of the common cold virus. Proc. Natl. Acad. Sci. USA 95:6774-78
83. Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, et al. 2012. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog. 8:e1002930
84. Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, et al. 2012. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20:303-14
85. Lok SM,Kostyuchenko V, NybakkenGE, Holdaway HA,Battisti AJ, et al. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-17
86. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization ofWest Nile virus. PLoS Pathog. 7:e1002111
87. Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. 2013. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl. Acad. Sci. USA 110:6795-99
88. Fibriansah G, Ng TS, Kostyuchenko VA, Lee J, Lee S, et al. 2013. Structural changes of dengue virus when exposed to 37°C. J. Virol. 87:7585-92
89. Bothner B, Dong XF, Bibbs L, Johnson JE, Siuzdak G. 1998. Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem. 273:673-76
90. Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ. 2009. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J. Virol. 83:7040-48
91. Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, et al. 2014. The mechanism and significance of cell type-dependent neutralization of flaviviruses. J. Virol. In press. doi: 10.1128/JVI.03690-13
92. Morens DM. 1994. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19:500-12
93. Guzman MG, Alvarez M, Halstead SB. 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 158:1445-59
94. Sun P, Bauza K, Pal S, Liang Z,Wu SJ, et al. 2011. Infection and activation of human peripheral blood monocytes by dengue viruses through the mechanism of antibody-dependent enhancement. Virology 421:245-52
95. KouZ,Lim JY, Beltramello M, QuinnM,ChenH, et al. 2011.Humanantibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology 410:240-47
96. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. 2007. The stoichiometry of antibodymediated neutralization and enhancement ofWest Nile virus infection. Cell Host Microbe 1:135-45
97. MoiML, Lim CK, Chua KB, Takasaki T, Kurane I. 2012. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells. PLoS Negl. Trop. Dis. 6:e1536
98. Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ. 2006. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human FcγRIA (CD64) or FcγRIIA (CD32). J. Virol. 80:10128-38
99. Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, et al. 2009. Dengue virus neutralization is modulated by IgG antibody subclass and Fcγreceptor subtype. Virology 394:175-82
100. Chawla T, Chan KR, Zhang SL, Tan HC, Lim AP, et al. 2013. Dengue virus neutralization in cells expressing Fcγreceptors. PLoS ONE 8:e65231
101. DejnirattisaiW, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-48
102. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-83
103. Tassaneetrithep B, Burgess T, Granelli-Piperno A, Trumpfheller C, Finke J, et al. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197:823-29
104. Kraus AA, Messer W, Haymore LB, de Silva AM. 2007. Comparison of plaque-and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45:3777-80
105. Nimmerjahn F,Ravetch JV. 2011. FcγRs in health and disease. Curr. Top. Microbiol. Immunol. 350:105-25
106. Schlesinger JJ, Foltzer M, Chapman S. 1993. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192:132-41
107. Mehlhop E, Ansarah-Sobrinho C, Johnson S, EngleM, Fremont DH, et al. 2007. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specificmanner. Cell Host Microbe 2:417-26
108. Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, et al. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization ofWest Nile virus. Cell Host Microbe 6:381-91
109. Oliphant T, Engle M, Nybakken G, Doane C, Johnson S, et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-30
110. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, et al. 2011. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fc-γreceptor and complement-dependent effector mechanisms. J. Virol. 22:11567-80
111. Chung KM, Thompson BS, Fremont DH, Diamond MS. 2007. Antibody recognition of cell surface-associated NS1 triggers Fc-γ receptor mediated phagocytosis and clearance of WNV infected cells. J. Virol. 81:9551-55
112. Yamanaka A, Kosugi S, Konishi E. 2008. Infection-enhancing and-neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J. Virol. 82:927-37
113. Laoprasopwattana K, LibratyDH, Endy TP, Nisalak A, Chunsuttiwat S, et al. 2007. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J. Infect. Dis. 195:1108-16
114. FlamandM,Megret F,Mathieu M, Lepault J,Rey FA,DeubelV. 1999. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J. Virol. 73:6104-10
115. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M. 2002. Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J. Clin. Microbiol. 40:376-81
116. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, et al. 2002. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 186:1165-68
117. Young PR, Hilditch PA, Bletchly C, HalloranW. 2000. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J. Clin. Microbiol. 38:1053-57
118. Despres P, Dietrich J, Girard M, Bouloy M. 1991. Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice. J. Gen. Virol. 72:2811-16
119. Schlesinger JJ, BrandrissMW, Cropp CB,Monath TP. 1986. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 60:1153-55
120. Putnak JR, Schlesinger JJ. 1990. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J. Gen. Virol. 71:1697-702
121. Henchal EA, Henchal LS, Schlesinger JJ. 1988. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 69:2101-7
122. Falgout B, Bray M, Schlesinger JJ, Lai CJ. 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 64:4356-63
123. Chung KM, Nybakken GE, Thompson BS, Engle MJ, Marri A, et al. 2006. Antibodies against West Nile virus non-structural (NS)-1 protein prevent lethal infection through Fcγreceptor-dependent and independent mechanisms. J. Virol. 80:1340-51
124. Akey DL, Brown WC, Dutta S, Konwerski J, Jose J, et al. 2014. Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science 343:881-85
125. EdelingMA, DiamondMS, FremontDH. 2014. Structural basis of flavivirus NS1 assembly and antibody recognition. Proc. Natl. Acad. Sci. USA 111:4285-90
126. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, et al. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6:741-50
127. Good-Jacobson KL, Shlomchik MJ. 2010. Plasticity and heterogeneity in the generation of memory Bcells and long-lived plasma cells: the influence of germinal center interactions and dynamics. J. Immunol. 185:3117-25
128. Luther SA, Maillard I, Luthi F, Scarpellino L, Diggelmann H, Acha-Orbea H. 1997. Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigenreactive T cells. J. Immunol. 159:2807-14
129. Diamond MS, Sitati E, Friend L, Shrestha B, Higgs S, Engle M. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-62
130. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, et al. 2012. Rapid and massive virusspecific plasmablast responses during acute dengue virus infection in humans. J. Virol. 86:2911-18
131. Zompi S, MontoyaM, PohlMO, Balmaseda A,Harris E. 2012. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl. Trop. Dis. 6:e1568
132. Finke D, Baribaud F, Diggelmann H, Acha-Orbea H. 2001. Extrafollicular plasmablast B cells play a key role in carrying retroviral infection to peripheral organs. J. Immunol. 166:6266-75
133. Jacob J, Kelsoe G, Rajewsky K,Weiss U. 1991. Intraclonal generation of antibody mutants in germinal centres. Nature 354:389-92
134. Manz RA, Thiel A, Radbruch A. 1997. Lifetime of plasma cells in the bone marrow. Nature 388:133-34
135. SlifkaMK,Matloubian M, AhmedR. 1995. Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol. 69:1895-902
136. Slifka MK, Antia R, Whitmire JK, Ahmed R. 1998. Humoral immunity due to long-lived plasma cells. Immunity 8:363-72
137. Balakrishnan T, Bela-Ong DB, Toh YX, FlamandM, Devi S, et al. 2011. Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PLoS ONE 6:e29430
138. WahalaWM,SilvaAM. 2011. The human antibody response to dengue virus infection. Viruses 3:2374-95
139. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, et al. 2011. Ligation of Fcγ receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc. Natl. Acad. Sci. USA 108:12479-84
140. Imrie A, Meeks J, Gurary A, Sukhbaatar M, Truong TT, et al. 2007. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol. 20:672-75
141. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. 2011. Memory B cells but not long-lived plasma cells possess antigen specificities for viral escape mutants. J. Exp. Med. 208:2599-606
142. Halstead SB. 2013. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 31:4501-7
143. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, et al. 2010. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185:5405-16
144. Yauch LE, Zellweger RM, Kotturi MF,Qutubuddin A, Sidney J, et al. 2009. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182:4865-73
145. An J, Zhou DS, Zhang JL, Morida H, Wang JL, Yasui K. 2004. Dengue-specific CD8+ T cells have both protective and pathogenic roles in dengue virus infection. Immunol. Lett. 95:167-74
146. Gil L, Lopez C, Lazo L, Valdes I, Marcos E, et al. 2009. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int. Immunol. 21:1175-83
147. Lazo L, Gil L, Lopez C, Valdes I, Marcos E, et al. 2010. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch. Virol. 155:1587-95
148. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, et al. 2011. A human challenge model for dengue infection reveals a possible protective role for sustained interferon γlevels during the acute phase of illness. Vaccine 29:3895-904
149. Duangchinda T, DejnirattisaiW, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, et al. 2010. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. USA 107:16922-27
150. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, et al. 2013. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. USA 110:E2046-53
151. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, et al. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921-27
152. Rothman AL. 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11:532-43
153. Dung NT, Duyen HT, Thuy NT, Ngoc TV, Chau NV, et al. 2010. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J. Immunol. 184:7281-87
154. Friberg H, Bashyam H, Toyosaki-Maeda T, Potts JA, Greenough T, et al. 2011. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci. Rep. 1:51